Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety and tolerability study of HRS-1893 in hypertrophic cardiomyopathy
CTR20252258Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-1893 in hypertrophic cardiomyopathy (HCM), sponsored by Shandong Sende. Started Jul 2025; status: active.
02
Drugs
HRS-1893
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on CTR20252258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252258.